Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown*, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Yan Li, Daniel W. Pierce, Evelyn Barnett, Jeffrey Marine, Monika Miranda, Ada Azaryan, Xujie Yu & 3 others Pilar Nava-Parada, Jay Mei, Thomas J. Kipps

*Corresponding author for this work

Research output: Contribution to journalLetter

25 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)e295-e298
JournalHaematologica
Volume101
Issue number7
DOIs
StatePublished - Jan 1 2016

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide
Agammaglobulinaemia tyrosine kinase

Keywords

  • BTK inhibitors
  • CC-292
  • Chronic lymphocytic leukemia
  • Refractory
  • Relapsed
  • Single-agent
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J., Sharman, J. P., Schreeder, M. T., ... Kipps, T. J. (2016). Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica, 101(7), e295-e298. https://doi.org/10.3324/haematol.2015.140806
Brown, Jennifer R. ; Harb, Wael A. ; Hill, Brian T. ; Gabrilove, Janice ; Sharman, Jeff P. ; Schreeder, Marshall T. ; Barr, Paul M. ; Foran, James M. ; Miller, Thomas P. ; Burger, Jan A. ; Kelly, Kevin R. ; Mahadevan, Daruka ; Ma, Shuo ; Li, Yan ; Pierce, Daniel W. ; Barnett, Evelyn ; Marine, Jeffrey ; Miranda, Monika ; Azaryan, Ada ; Yu, Xujie ; Nava-Parada, Pilar ; Mei, Jay ; Kipps, Thomas J. / Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. In: Haematologica. 2016 ; Vol. 101, No. 7. pp. e295-e298.
@article{8ad1042e5022458fa7e92fa0256c0c6c,
title = "Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia",
keywords = "BTK inhibitors, CC-292, Chronic lymphocytic leukemia, Refractory, Relapsed, Single-agent, Small lymphocytic lymphoma",
author = "Brown, {Jennifer R.} and Harb, {Wael A.} and Hill, {Brian T.} and Janice Gabrilove and Sharman, {Jeff P.} and Schreeder, {Marshall T.} and Barr, {Paul M.} and Foran, {James M.} and Miller, {Thomas P.} and Burger, {Jan A.} and Kelly, {Kevin R.} and Daruka Mahadevan and Shuo Ma and Yan Li and Pierce, {Daniel W.} and Evelyn Barnett and Jeffrey Marine and Monika Miranda and Ada Azaryan and Xujie Yu and Pilar Nava-Parada and Jay Mei and Kipps, {Thomas J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.3324/haematol.2015.140806",
language = "English (US)",
volume = "101",
pages = "e295--e298",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

Brown, JR, Harb, WA, Hill, BT, Gabrilove, J, Sharman, JP, Schreeder, MT, Barr, PM, Foran, JM, Miller, TP, Burger, JA, Kelly, KR, Mahadevan, D, Ma, S, Li, Y, Pierce, DW, Barnett, E, Marine, J, Miranda, M, Azaryan, A, Yu, X, Nava-Parada, P, Mei, J & Kipps, TJ 2016, 'Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia', Haematologica, vol. 101, no. 7, pp. e295-e298. https://doi.org/10.3324/haematol.2015.140806

Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. / Brown, Jennifer R.; Harb, Wael A.; Hill, Brian T.; Gabrilove, Janice; Sharman, Jeff P.; Schreeder, Marshall T.; Barr, Paul M.; Foran, James M.; Miller, Thomas P.; Burger, Jan A.; Kelly, Kevin R.; Mahadevan, Daruka; Ma, Shuo; Li, Yan; Pierce, Daniel W.; Barnett, Evelyn; Marine, Jeffrey; Miranda, Monika; Azaryan, Ada; Yu, Xujie; Nava-Parada, Pilar; Mei, Jay; Kipps, Thomas J.

In: Haematologica, Vol. 101, No. 7, 01.01.2016, p. e295-e298.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

AU - Brown, Jennifer R.

AU - Harb, Wael A.

AU - Hill, Brian T.

AU - Gabrilove, Janice

AU - Sharman, Jeff P.

AU - Schreeder, Marshall T.

AU - Barr, Paul M.

AU - Foran, James M.

AU - Miller, Thomas P.

AU - Burger, Jan A.

AU - Kelly, Kevin R.

AU - Mahadevan, Daruka

AU - Ma, Shuo

AU - Li, Yan

AU - Pierce, Daniel W.

AU - Barnett, Evelyn

AU - Marine, Jeffrey

AU - Miranda, Monika

AU - Azaryan, Ada

AU - Yu, Xujie

AU - Nava-Parada, Pilar

AU - Mei, Jay

AU - Kipps, Thomas J.

PY - 2016/1/1

Y1 - 2016/1/1

KW - BTK inhibitors

KW - CC-292

KW - Chronic lymphocytic leukemia

KW - Refractory

KW - Relapsed

KW - Single-agent

KW - Small lymphocytic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84977137696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977137696&partnerID=8YFLogxK

U2 - 10.3324/haematol.2015.140806

DO - 10.3324/haematol.2015.140806

M3 - Letter

VL - 101

SP - e295-e298

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -